Filtered By:
Cancer: Carcinoma

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 3372 results found since Jan 2013.

Frizzled-3 suppression overcomes multidrug chemoresistance by Wnt/ β-catenin signaling pathway inhibition in hepatocellular carcinoma cells
This study aimed to identify a potential target in HCC chemotherapy. The FZD3 expression variant in HCC cell lines was detected by RT-qPCR and western blotting. The FZD3 expression in the early recurrent HCC group (RE group) and the non-early recurrent HCC group (non-RE group) was measured by RT-qPCR. Then, the 50% inhibitory concentrations (IC50) in HCC cell lines were studied by MTT assay. TOP/FOP FLASH luciferase assay was performed to measure TCF-binding activities. We found that FZD3 was upregulated in three HCC cell lines, and the FZD3 expression was significantly higher in the RE group than in the non-RE group (P = ...
Source: Journal of Chemotherapy - February 27, 2023 Category: Cancer & Oncology Authors: Zifan Meng Qing Liu Yanfei Liu Yuanming Yang Changfeng Shao Shaoqiang Zhang Source Type: research

Molecules, Vol. 28, Pages 2191: Potential of siRNA-Bearing Subtilosomes in the Treatment of Diethylnitrosamine-Induced Hepatocellular Carcinoma
grawal Mohammad Owais Therapeutics, based on small interfering RNA (siRNA), have demonstrated tremendous potential for treating cancer. However, issues such as non-specific targeting, premature degradation, and the intrinsic toxicity of the siRNA, have to be solved before they are ready for use in translational medicines. To address these challenges, nanotechnology-based tools might help to shield siRNA and ensure its specific delivery to the target site. Besides playing a crucial role in prostaglandin synthesis, the cyclo-oxygenase-2 (COX-2) enzyme has been reported to mediate carcinogenesis in various types of canc...
Source: Molecules - February 27, 2023 Category: Chemistry Authors: Fauzia Jamal Ghufran Ahmed Mohammad Farazuddin Ishrat Altaf Saba Farheen Qamar Zia Asim Azhar Hira Ahmad Aijaz Ahmed Khan Satyanarayana Somavarapu Anshu Agrawal Mohammad Owais Tags: Article Source Type: research

The prognostic value of DAAM2 in lower grade glioma, liver cancer, and breast cancer
CONCLUSION: DAAM2 had a specific value in foretelling the prognosis of LGG, LIHC, and BRCA. High expression level of DAAM2 has longer survival rates in LGG and LIHC. The knockdown of DAAM2 retards the proliferation, invasion, and migration of BRCA cells. This study provides a novel sight of DAAM2 into the exploration of a potential biomarker in pan-cancer.PMID:36790676 | DOI:10.1007/s12094-023-03111-x
Source: Clinical Breast Cancer - February 15, 2023 Category: Cancer & Oncology Authors: Zeying Li Xiao Wei Yichao Zhu Source Type: research

Targeting SHP2 reverses BRAF inhibitor tolerance in anaplastic thyroid carcinoma
CONCLUSION: The SHP2 inhibitor SHP099 can effectively reverse the drug resistance of dabrafenib through inhibiting the reactivated RAS signaling pathway in anaplastic thyroid cancer.The combination of dabrafenib with SHP2 inhibitor has shown significant tumor suppressive effects for dabrafenib-resistant cells and it may be a new therapeutic strategy with longer lasting therapeutic benefits.PMID:36786145 | DOI:10.2174/1871520623666230214093122
Source: Cancer Control - February 14, 2023 Category: Cancer & Oncology Authors: Tao Tang Jie Zhou Li-Xin Zhang Gang Yang Wei-Nan Li Jian-Jiao Zhu Yong-Fu Xiong Jing-Dong Li Source Type: research

Cancers, Vol. 15, Pages 1158: Unique Metabolic Contexts Sensitize Cancer Cells and Discriminate between Glycolytic Tumor Types
nning Cancer cells utilize variable metabolic programs in order to maintain homeostasis in response to environmental challenges. To interrogate cancer cell reliance on glycolytic programs under different nutrient availabilities, we analyzed a gene panel containing all glycolytic genes as well as pathways associated with glycolysis. Using this gene panel, we analyzed the impact of an siRNA library on cellular viability in cells containing only glucose or only pyruvate as the major bioenergetic nutrient source. From these panels, we aimed to identify genes that elicited conserved and glycolysis-dependent changes in cellu...
Source: Cancers - February 11, 2023 Category: Cancer & Oncology Authors: Jonathan A. Chacon-Barahona Jeffrey P. MacKeigan Nathan J. Lanning Tags: Article Source Type: research

ANXA2 as a novel substrate of FBXW7 promoting esophageal squamous cell carcinoma via ERK phosphorylation
In conclusion, this study provided evidence that FBXW7 loss of function could promote esophageal cancer through ANXA2 overexpression, and this novel regulation pathway may be used as an efficient target for ESCC treatment.PMID:36758484 | DOI:10.1016/j.bbrc.2023.01.082
Source: Biochemical and Biophysical Research communications - February 9, 2023 Category: Biochemistry Authors: Zongfei Li Yunzhi Pan Jiayi Yao Yingyin Gao Yulan Qian Minxue Zheng Sai Ma Source Type: research

Lnc-AIFM2-1 promotes HBV immune escape by acting as a ceRNA for miR-330-3p to regulate CD244 expression
Chronic hepatitis B (CHB) virus infection is a major risk factor for cirrhosis and hepatocellular carcinoma (HCC). Hepatitis B virus (HBV) immune escape is regulated by the exhaustion of virus-specific CD8+ T cells, which is associated with abnormal expression of negative regulatory molecule CD244. However, the underlying mechanisms are unclear. To investigate the important roles of non-coding RNAs play in CD244 regulating HBV immune escape, we performed microarray analysis to determine the differential expression profiles of long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and mRNAs in patients with CHB and patients wi...
Source: Frontiers in Immunology - February 9, 2023 Category: Allergy & Immunology Source Type: research

RNF6 activates TGF- β1/c-Myb pathway to promote EMT in esophageal squamous cell carcinoma
ConclusionRNF6 promotes the proliferation, invasion, and migration of ESCC cells possibly by activating the TGF-β1/c-Myb pathway and affects the progression of ESCC.
Source: Frontiers in Oncology - February 9, 2023 Category: Cancer & Oncology Source Type: research

Synergistic antitumor effect of histone deacetylase class IIa inhibitor with lenvatinib in hepatocellular carcinoma
ConclusionClass IIa HDACI and lenvatinib combination therapy induces apoptosis by downregulating FGFR4 and blocking the FGFR signaling in FGFR4-positive HCC cell lines and has demonstrated synergistic antitumor effects and safety. This combination therapy overcomes the problems of conventional therapies and will be beneficial for FGFR4-positive HCC patients.
Source: Hepatology International - February 4, 2023 Category: Infectious Diseases Source Type: research